On March 25th, Jiangsu Ruike Biotechnology Co., Ltd (hereinafter referred to as "Ruike Biotechnology", stock code: 02179.HK) and Shanghai Rongsheng Biopharmaceutical Co. (hereinafter referred to as "Rongsheng Biopharmaceuticals") in Shanghai. At the meeting, both parties signed a strategic cooperation agreement on the new adjuvant vaccine project and discussed the details of the project.

Adjuvant is an important component in the development of vaccines, and new adjuvants have become the key to the success of innovative vaccine research and development. According to the terms of the agreement, the two parties will jointly carry out the development of new adjuvant vaccines, with Ruike Biologicals providing new adjuvants independently developed based on the new adjuvant technology platform, and Rongsheng Biologicals providing viral antigens independently designed by Rongsheng Biologicals. The project will improve the immunogenicity of existing Rongsheng Bio's vaccines under development by empowering them with novel adjuvants for the purpose of optimizing immunization procedures.

Dr. Yong Liu, Founder, Chairman and General Manager of Rongsheng Bio, said, "This collaboration is an important milestone for Rongsheng Bio's adjuvant-enabled industry chain partners. Novel adjuvants play a crucial role in the development and application of innovative vaccines. Relying on its self-developed novel adjuvant technology platform, Ruike Biologicals has successfully developed a number of innovative vaccines with novel adjuvants, which have excellent clinical performance, high competitiveness and market potential. We look forward to the early fruits of our strategic cooperation with Rongsheng Bio, and believe that our cooperation will further promote the innovative development of human vaccines."

Mr. Zhu Shaorong, Founder and Chairman of Rongsheng Biologicals, said, "Rongsheng Biologicals has built a key core technology platform for 'viral+bacterial' vaccines based on independent research and development, possesses large-scale production capacity, and has achieved breakthroughs in technological innovation and upgrading in the scientific research of a number of vaccine products under development. This strategic cooperation aims at the vaccine cutting-edge innovation and market demand, making full use of the scientific research advantages and innovation achievements of both parties, and continuing in-depth cooperation to jointly promote the research and development and commercialization of new adjuvant vaccines. We are confident that we will work together with Ruike Biotechnology to realize the results of the strategic cooperation and improve clinical performance for the benefit of human life and health as well as public health and safety."

https://mp.weixin.qq.com/s?__biz=MzkyMDEzMzQxMQ==&mid=2247485735&idx=1&sn=923a262e01b0ae078ff45dc81dcba811&chksm=c196c36bf6e14a7d0baf22bf8a26358d79395d42431f3bdfdafa5c61fb5fdd24518ba1ba0794&mpshare=1&scene=1&srcid=0328kXDU1JwYrsxwIjHiRNY8&sharer_shareinfo=2f210385fd5db7b6d7edd01d48abe644&sharer_shareinfo_first=2f210385fd5db7b6d7edd01d48abe644#rd